Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy through Optimization of the IgG Framework  by Offringa, Rienk & Glennie, Martin J.
Cancer Cell
PreviewsDevelopment of Next-Generation Immunomodulatory
Antibodies for Cancer Therapy through Optimization
of the IgG FrameworkRienk Offringa1,* and Martin J. Glennie2
1Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Im Neuenheimer Feld 280,
69120 Heidelberg, Germany
2Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona Road, Southampton SO16 6YD, UK
*Correspondence: r.offringa@dkfz.de
http://dx.doi.org/10.1016/j.ccell.2015.08.008
In this issue of Cancer Cell, Dahan and colleagues demonstrate that the Fc region has a significant impact
on the therapeutic capacity of checkpoint inhibitor antibodies targeting the PD-1/PD-L1 axis in pre-clinical
tumor models. This work provides important insights with respect to the further clinical development of
checkpoint inhibitors.Systematic comparison of different anti-
body (Ab) formats in mouse tumor
models revealed that the efficacy of
anti-mouse PD-1 Abs solely depends on
T cell activation through PD-1-blockade
and can be compromised by two Fcg re-
ceptor (FcgR)-dependent mechanisms:
Ab-dependent cell-mediated cytotoxicity
(ADCC)-mediated depletion of PD-1-pos-
itive effector T cells and FcRgIIB-depen-
dent agonist activity toward PD-1. In
contrast, the efficacy of anti-mouse PD-
L1 Abs does not merely involve PD-L1-
blockade, but critically depends on
ADCC-mediated deletion of PD-L1-posi-
tive myeloid subsets in the tumor micro-
environment. This latter observation is
particularly important because it adds
new insight into how immunomodulatory
Abs work and supports the role of
myeloid cells in immune suppression.
Until recently, the recipe for designing
an Ab-based oncology drug read as fol-
lows. If the drug is to eliminate target
cells, use a human immunoglobulin G1
(IgG1) framework that engages activatory
FcgRs for efficient recruitment of im-
mune effector mechanisms. If one aims
at changing cell behavior by blocking
receptor:ligand engagement, select a
human IgG4 or IgG2, or alternatively an
Fc null IgG1, that does not mediate im-
mune-mediated deletion. More recently,
several new flavors have been added to
this palette (Figure 1).
The first evidence that FcgR interaction
could contribute to therapeutic impact
beyond the recruitment of ADCC came
from a study by Wilson et al. (2011),showing that the anti-tumor efficacy of
agonist Abs targeting DR5, in contrast to
that of the anti-CD20 Ab rituximab, did
not require engagement of the activatory
FcgRs. Instead, availability of the inhibi-
tory receptor FcgRIIB was found to
be sufficient in this respect. Similar find-
ings for an agonistic Ab targeting CD40
indicated that this could be a general
feature of agonist Abs targeting TNFR
family members and furthermore sug-
gested that FcgRIIB engagement may
not only be sufficient, but even essential,
for agonist function. These data pro-
voked the hypothesis that the main role
of FcgR engagement involved the crea-
tion of multimeric Ab aggregates capable
of inducing receptor clustering at the
target cell surface (Wilson et al., 2011).
Subsequent studies substantiated the
importance of FcgRIIB-mediated clus-
tering for the function of agonist Abs (Li
and Ravetch, 2011, 2012, 2013; White
et al., 2011, 2013, 2015)—in particular,
for Abs targeting the activatory immune
receptors CD40, 4-1BB, and CD28 as
well as for the TNFR-family death re-
ceptors DR4, DR5, and Fas—and shed
more light on the unique and rather unex-
pected role of FcyRIIB in this respect.
While this inhibitory receptor was tradi-
tionally regarded as a potential obstacle
for Ab-based drug action, these studies
demonstrated that it was of crucial
importance for empowering agonist Abs
to stimulate cell-mediated immunity or
induce target cell death.
A limitation of these findings with
respect to the development of clinicalCancer Cell 28, Sedrugs lays in the important differences
between the effector functions of mouse
and human IgG-isotypes. Of the available
mouse IgG-isotypes, mouse IgG1 is the
most potent format for agonist Abs,
which is directly related to its relatively
strong and rather selective binding to
FcgRIIB (Li and Ravetch, 2011, 2012,
2013; White et al., 2011, 2013, 2015).
However, the human IgG repertoire lacks
an analog of mouse IgG1 with compara-
ble FcgRIIB binding capacity. This pre-
sents a hurdle in translating the perfect
pre-clinical format of agonist Abs to a
clinical drug. Nevertheless, alternative
strategies for potentiating agonist Abs
have been identified, such as through
modifications in the human IgG1 domain
that increase FcgRIIB-binding (White
et al., 2013 and references therein) or by
using the unexpected agonist properties
of human IgG2, a subclass that shows
relatively little FcgR-dependent effector
activity (White et al., 2015). The agonistic
properties of human IgG2 appear to be
controlled by its unique arrangement of
hinge-region disulfide bonds, which result
in a highly compact inflexible structure
able to promote receptor crosslinking
without FcgR engagement (Figure 1).
In this issue of Cancer Cell, Dahan et al.
(2015) now show that the selection of the
optimal IgG format is equally important
for checkpoint inhibitors and depends
on the target concerned. An anti-PD-1
Ab with mouse IgG1 format was found
to display suboptimal efficacy in tumor
models as compared to a mutated
variant incapable of FcgR engagement.ptember 14, 2015 ª2015 Elsevier Inc. 273
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Figure 1. Overview of the Four Current Classes of Immunomodulatory Abs
The antagonist function of checkpoint inhibitors was initially thought to reside in their capacity to physically
block interaction between the inhibitory ligand-receptor pair (1). Recent data indicate that the biological
activity of several checkpoint inhibitors may also, or even primarily, rely on depletion of suppressive im-
mune cell subsets through the Fc-dependent recruitment of immune effector cells expressing activatory
FcRs (2). The function of the majority of agonist immunostimulatory Abs was found to depend on creation
of multimeric aggregates at the surface of FcgRIIB-positive hematopoietic cells that are capable of
inducing receptor clustering at the target cell surface (3). Most recently, the human IgG2 framework
was found to endow agonist Abs with greatly enhanced, FcgR-independent activity, probably due to
more optimal arrangement of the IgG Fab-domains allowing receptor clustering by non-multimerized
Abs (4). Notably, this modification does not only change the strength of the agonist signal, but is also
expected to result in a systemic signal that impacts on target-positive immune cells independent of co-
localized FcgRIIB-positive accessory cells.
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PreviewsThis indicated that the mouse IgG1
format interfered with the antagonist
activity of this Ab. Further experiments
in FcgRIIB-deficient mice supported the
notion that this interference is due to
the FcgRIIB-mediated empowerment of
an agonist function. The good news with274 Cancer Cell 28, September 14, 2015 ª20respect to clinical drug design is that,
as mentioned, none of the human IgG
isotypes display appreciable binding to
FcgRIIB. As such, the choice of a human
IgG4 format for the two clinical anti-PD-1
leads in this class, nivolumab and pem-
brolizumab, guided by the intent to avoid15 Elsevier Inc.ADCC-mediated depletion of effector
T cells, appears to be sound.
Nevertheless, the study by Dahan et al.
(2015) also shows that the choice of IgG
format may offer room for improvement
for clinical Abs targeting PD-L1, in that
the mouse IgG2a framework renders the
best efficacy in the pre-clinical setting.
The data show that depletion of immune
suppressive myeloid subsets in the tu-
mor microenvironment, as mediated by
the mouse IgG2a format, is essential for
therapeutic efficacy. These findings are
reminiscent of prior observations with
Ab targeting mouse CTLA-4, OX40, and
GITR, in that a gain of function of the
mouse IgG2a format involved their capac-
ity to deplete T-regulatory cells (reviewed
in Furness et al., 2014). However, the find-
ings by Dahan et al. (2015) leave unre-
solved why blocking of PD-1 suffices to
deliver tumor shrinkage, yet blockade of
its main known ligand PD-L1 falls short
of mobilizing a therapeutic anti-tumor
response without depletion of PD-L1-
positive myeloid cells. One potential
explanation would be that the latter is
needed to overcome the immune inhibi-
tory influence of PD-L2.
It will be important to see whether the
functional differences between these
pre-clinical Abs are reflected by the rela-
tive efficacy of the various anti-human
PD-1 and PD-L1 Abs that are currently in
clinical testing. Since the FcR-dependent
functional properties of the mouse IgG2a
format are closely reflected by that of
human IgG1, the importance of depleting
activity for the clinical efficacy of anti-
human PD-L1 Abs can be readily ad-
dressed. Notably, only one of the four
currently available clinical anti-human
PD-L1 Abs, MSB001078C, has been en-
gineered with a human IgG1 isotype,
while the other three are built on either
huIgG4 (BMS-936559) or Fc null variants
of huIgG1 (MPDL3280A and MEDI4736).
Testing in humans is essential, because
the lack of conservation between the hu-
man and mouse Fc/FcgR-system cannot
be fully bridged by experiments in vitro
and in human FcgR transgenic mice. As-
pects that are difficult to model include
differences in expression patterns of
FcgRs on immune cell subsets, the distri-
bution of these FcgR-expressing cell sub-
sets in lymphoid organs and solid tumors,
and the availability of these receptors due
to IgG-occupancy. Despite the promising
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Previewsdata by Dahan et al. (2015), with no evi-
dence for toxicity toward normal somatic
tissues, clinical trials with MSB001078C
need to proceed with care, because PD-
L1 is expressed at considerable levels in
several normal human tissues, including
lung.
In conclusion, new insights into the
function of the IgG isotypes have enabled
modulation of the biological properties
of immune stimulatory Abs, and clinical
trials with more potent formats are immi-
nent. While it is conceivable that fine-
tuning will culminate in mono-specific
drugs with improved therapeutic index,
the importance of tailoring the IgG Fcregions to each target will also add a
layer of complexity to the design of bi-
and dual-specific Abs that are directed
against two different surface molecules.REFERENCES
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In this issue ofCancer Cell, studies fromMazor and colleagues and Kim and colleagues use a combination of
epigenetic and genetic approaches to reveal a complex evolutionary process underlying two of the biggest
challenges facing neuro-oncology, specifically glioblastoma malignant progression and treatment resis-
tance.Gliomas are the most common malignant
brain tumor of adults and are highly treat-
ment resistant. Grade IV gliomas are
called glioblastoma multiforme (GBM)
and are currently classified as primary
GBM or secondary GBM, the latter of
which are presumed to arise from a
lower grade tumor. Secondary GBMs
frequently harbor mutations in IDH1 or
IDH2 and are thought to have a more
favorable response to therapy (Hegi
et al., 2005). Current therapy for GBM is
focal external beam irradiation with
concomitant temozolomide. This is fol-
lowed by 6 months of temozolomide
therapy, which is thought to result in a
marginal 2.5-month improvement in
survival (Stupp et al., 2005). Unfortu-
nately, GBM remains almost universally
fatal. A recent sequencing based analysis
of paired gliomas from diagnosis andrelapse has revealed significant changes
in both driver genes and pathway alter-
ations at relapse, suggesting that tar-
geted therapies based on the tumor
genome at diagnosis are doomed to fail-
ure (Figure 1A) (Johnson et al., 2014).
Two studies reported in this issue of Can-
cer Cell by Mazor et al. (2015) and Kim
et al. (2015a) aim to answer two major
challenges in neuro-oncology, the mech-
anism driving malignant progression of
low grade gliomas, and the mechanism
of treatment resistance in GBM.
The study by Mazor et al. (2015) uses
a combined genetic and epigenetic
analysis to elucidate the driver events
and evolutionary pathways driving ma-
lignant progression of IDH mutant low
grade gliomas. Across 19 matched tumor
samples from diagnosis and progres-
sion, both genetic events and epigeneticevents were different in the recurrent
tumor as compared to the matched
untreated primary tumor. The hyperme-
thylated, ‘‘CIMP +ve’’ tumors frequently
demonstrated loss of CpG methylation
at a subset of genes in the recurrent tu-
mors, suggesting that ‘‘demethylated’’
genes might be transcriptionally activated
and acting as oncogenes. Most interest-
ingly, CpG moieties that lose methylation
during malignant progression converge
on biological pathways that have been
previously identified asGBMdrivers using
genetic approaches: components of the
G1/S cell cycle checkpoint and the RB
pathway.
The authors proceed to construct phy-
loepigenetic and phylogenetic trees from
GBM patients at presentation and recur-
rence and found that both DNA methyl-
ation (epigenetic) and mutational eventsptember 14, 2015 ª2015 Elsevier Inc. 275
